By Caroline Copley ZURICH (Reuters) - Buying Alexion Pharmaceuticals Inc would help Roche make a splash in the newly lucrative area of rare or so-called orphan diseases, but it could command a price that the Swiss drug maker is ultimately not willing to pay. Two people familiar with the matter have told Reuters that the Basel-based firm is seeking financing for a potential bid for Alexion, which specializes in the treatment of rare diseases. ...
From Around the Web
http://facebookgameshelp.com/index.php?do=/blog/2586/the-concealed-reality-regarding-safe-weight-loss-pills/
http://ecoles.ac-rouen.fr/encyclo/index.php?title=Discover_The_Critical_Details_On_Weight_Loss_Products
http://emiratesbizz.com/index.php?do=/blog/3983/the-puzzles-i-reveal-on-all-natural-weight-loss-supplements/
http://gateclub.net/blogs/viewstory/136490
http://hostmaster.terhorstnet.nl/wiki/The_Reasons_For_All_Natural_Slimming_Products
No comments:
Post a Comment